Democrats Control Congress — Can They Fix the U.S. Healthcare System?

Democrats' healthcare priorities and bipartisan cooperation space after retaking Congress, plus the state-level main battleground.
After the U.S. midterm elections, Democrats won both chambers of Congress and healthcare reform returned to Washington's agenda, but Trump's veto power makes major legislation difficult. Vox reporter Dylan Scott analyzes that Democrats' most unified priority is repealing the roughly $1 trillion in Medicare/Medicaid cuts in the One Big Beautiful Bill Act, though the next two years are more likely about political pressure than policy. Bipartisan room exists on site neutrality payment reform, fixing the No Surprises Act arbitration backlog, and drug price international referencing and expanding Medicare drug negotiations. Short-term substantive change is most likely at the state level: Democratic wins in Texas and Georgia could restart Medicaid expansion talks, while public option experiments and private equity healthcare regulation advance in multiple states. Democrats face a key choice: build internal consensus around healthcare reform for 2028, or let healthcare become a primary dividing point again.
After the U.S. midterm elections, Democrats won both chambers of Congress, and healthcare reform is once again a central issue in Washington. But Trump still occupies the White House, which means any major legislation could face a veto. In a joint podcast from News Not Noise and Vox, Vox healthcare reporter Dylan Scott and Jessica Yellen discussed in depth what Democrats can and cannot do within limited political space, and where the two parties might find room for cooperation on specific issues.
First Priority: Repealing the Medicaid Cuts in the One Big Beautiful Bill Act
According to Dylan Scott's observations, the Democrats' clearest and most unified priority is repealing the roughly $1 trillion in Medicare and Medicaid cuts in the One Big Beautiful Bill Act that Republicans passed last year. Incoming House Speaker Hakeem Jeffries has publicly listed this as his top task, and multiple newly elected lawmakers confirmed to Scott within a week of the election that if they could choose only one thing, it would be this.
But the practical obstacles are equally obvious. Trump will not sign a bill repealing his own signature legislation, so the real logic behind the Democrats' push has three layers: fulfilling campaign promises, forcing Republicans to vote repeatedly on a sensitive issue to maintain political pressure, and paving the way for actually repealing these cuts after retaking the White House in 2028. Scott's assessment is that the next two years are more likely to be about political mobilization than policy implementation, but that process itself has strategic value.

Three Areas Where Bipartisan Consensus May Be Possible
Although the two parties have vastly different long-term visions for the healthcare system, Scott believes everyone acknowledges the system is "seriously broken," and there is willingness to cooperate on a limited set of issues.
1. Medicare Payment Reform and "Site Neutrality"
One issue flagged by think tanks on both sides is site neutrality: the same medical procedure performed in a hospital outpatient department may cost five times as much as in an independent physician's office. This price differential based solely on physical location is seen as absurd by both parties. Scott notes that conservative and liberal thought leaders alike believe the next Congress should prioritize targeted payment reforms like this, because "saving money for Medicare is saving money for taxpayers" is a narrative both parties can accept.
Site neutrality is a core principle in U.S. Medicare payment reform: the same medical service, whether provided by a hospital outpatient department, an independent physician's office, or another setting, should be reimbursed by Medicare at the same rate. Under the current system, hospital outpatient departments receive higher facility fees because they are classified as "hospital services," causing the same procedure to cost several times more in a hospital setting than in an independent clinic. Supporters argue that this price gap distorts healthcare providers' location decisions, driving hospitals to acquire clinics in order to raise charges, thereby pushing up overall healthcare spending. Opponents (mainly hospital associations) argue that hospitals bear higher fixed costs and public-service burdens such as emergency care and teaching, and that uniform rates would weaken their operating capacity. In recent years, MedPAC and bipartisan think tanks have recommended gradually tightening site neutrality rules, but congressional efforts have repeatedly faced hospital lobbying resistance.
2. Fixing the Arbitration Backlog Under the No Surprises Act
The No Surprises Act was originally designed to protect patients from exorbitant bills charged by out-of-network providers in emergency situations and similar scenarios. It has indeed protected patients, but the arbitration process it established has created a massive backlog in practice. Insurers accuse providers of exploiting the arbitration process to maximize payments, and even attribute some premium increases to it. Scott believes that industry dissatisfaction combined with voters' concerns about affordability gives this issue real bipartisan momentum for resolution.
The No Surprises Act took effect in 2022, with the core purpose of protecting patients from balance billing in scenarios such as emergency care or when out-of-network doctors practice at in-network facilities — patients only need to pay the in-network cost-sharing amount. For payment disputes between insurers and providers, the law established an Independent Dispute Resolution (IDR) arbitration process: both parties submit offers, and the arbitrator selects one. However, the volume of IDR cases has far exceeded expectations, causing severe backlogs and prolonged arbitration timelines. Insurers accuse some providers (especially private-equity-backed emergency medicine, anesthesiology, and radiology groups) of submitting high-priced cases in bulk to maximize payments and passing costs on to premiums; providers counter that insurers' initial payments are too low. Reform directions include introducing precedent-setting rulings, establishing batch arbitration rules, and raising filing thresholds — both parties have incentive to push on this issue.
3. Prescription Drug Prices: Trump's Unconventional Stance Creates Space
According to ongoing KFF surveys, 43% of Americans say they have not taken medication as prescribed in the past year due to cost, showing that drug prices remain an urgent pain point for ordinary people. Scott characterizes Trump's record on drug prices as "more sound than substance" — Trump Rx mainly benefits cash-paying patients and offers limited help to those with insurance. But Trump's unorthodox stance on drug prices — supporting government intervention to lower them — has actually created legislative opportunities for Democrats.

Two specific directions are worth watching: First, Trump has repeatedly said the U.S. should not pay more for drugs than other countries, hinting at support for international price referencing, to which congressional Democrats are open; second, after Medicare drug negotiations were launched during the Biden era, the Trump administration continued the negotiation process, and Democrats such as Frank Pallone have proposed including more drugs in the negotiation scope, especially for the Medicare elderly population.
International reference pricing refers to anchoring U.S. drug prices to price levels in reference countries (such as Canada, France, Japan, etc.), typically using the lowest or average price from a basket of countries. Trump has repeatedly raised this idea during his tenure, arguing that the U.S. should not pay far more than other developed countries for the same drug. Supporters argue this would directly reduce Medicare and commercial insurance drug spending; opponents warn that pharmaceutical companies might reduce R&D investment or circumvent the anchoring by limiting supply in reference countries. Meanwhile, Medicare drug negotiations (authorized by the Inflation Reduction Act) have begun price negotiations for the first batch of 10 drugs, and the Trump administration has continued this process. Democrats like Frank Pallone advocate expanding the scope of negotiated drugs and accelerating the negotiation timeline, especially for drugs with high usage among the elderly. These two paths — international reference pricing and expanded negotiation — could potentially complement each other legislatively.
Is There a Realistic Path to Restoring Medicaid Cuts?
Scott is cautious about this. He expects Democrats to push repeal through budget reconciliation, but a Trump veto is almost certain. However, a middle-ground proposal from Senator Warnock is worth noting: rather than directly repealing the new Medicaid work requirements, delay them by two years. Scott believes such compromise proposals are unlikely to become law, but they show that Democrats are exploring multiple pressure paths rather than just full repeal.

The State Level Is the Main Battleground for Short-Term Change
Given divided government in Washington, Scott believes short-term substantive change is most likely to happen at the state level. Democrats won multiple gubernatorial and state legislative elections, creating conditions for policy experimentation.
Medicaid expansion: The ACA allows states to expand Medicaid to people near the poverty line. Most states have adopted it, but about 10 states have not. Georgia and Texas elected Democratic governors this time and won at least one state legislative chamber. If Texas can design an expansion plan acceptable to the Republican-controlled state senate, a million people could gain coverage overnight — a massive impact.
Public option: Democratic gubernatorial candidates in Wisconsin, New Mexico, and Maine campaigned on a public option. Several states have been running public options for years. Whether Wisconsin, under a new Democratic governor and state legislature control, will advance a similar plan will test whether this experiment can spread.
Abortion rights protection: Democrats in Georgia and North Carolina have at least secured enough votes to block further restrictions; states like Wisconsin may attempt to enshrine abortion rights in state law or state constitutions.
Private equity and healthcare: Candidates in states like New Mexico explicitly raised that private equity acquiring healthcare institutions and operating them with extreme profit models is a core problem, and want to restrict private equity ownership of healthcare companies or ensure clinical decisions are based on patient interests rather than financial returns. Scott notes this is a relatively new issue with no clear policy solutions yet, but state-level debate will increase significantly in the coming years.

Medicare for All and the Democrats' Consensus Dilemma
Scott summarizes the Democrats' core question for the next two years as: Will they build consensus around governing goals for 2028, or will healthcare once again become a dividing point between the party's progressive and moderate wings?
He compares two historical periods. In 2006, Democrats won congressional majorities at the end of an unpopular Republican president's term, and over the following two years built fairly solid consensus around healthcare reform. In 2008, Hillary Clinton's and Barack Obama's healthcare plans differed very little — essentially a prototype of the ACA — laying the foundation for later legislation, even though passage was still difficult. During 2018-2020, however, healthcare was used more to differentiate candidates in presidential primaries, becoming a point of division rather than unity, which left Democrats without a consensus foundation for advancing healthcare reform after Biden took office, and healthcare reform was shelved in the early agenda.
Scott observes some positive signals: after previous battles, Democrats recognize the need to focus on common ground — universal coverage and reducing out-of-pocket costs — even if the paths to achieving them still differ. Whether this consensus can be maintained for two years will determine whether there is an opportunity to push major change in 2029.
Medicare for All has long reflected a spectrum of views within the Democratic Party. Progressives (such as Bernie Sanders) advocate a single-payer system, abolishing private insurance and having the federal government finance and pay uniformly; moderates favor a public option — a government-run insurance plan offered alongside the ACA marketplaces to compete with private insurance without replacing it. During the 2018-2020 primaries, this divide became a signature issue differentiating candidates, making it difficult for the party to form a unified legislative proposal. The 2006-2008 comparison Scott cites shows that when Democrats focus on the common goals of "expanding coverage + reducing out-of-pocket costs" rather than specific institutional paths, they are more likely to build a consensus foundation for legislation after taking power. The current positive signal for Democrats is that factions are beginning to accept universal coverage and affordability as a common platform, temporarily setting aside path disagreements.
One-line Summary
Democrats' healthcare priorities and bipartisan cooperation space after retaking Congress, and the state-level main battleground.
Paragraph Summary
After the U.S. midterm elections, Democrats won both chambers of Congress and healthcare reform returned to Washington's agenda, but Trump's veto power makes major legislation difficult to enact. Vox reporter Dylan Scott analyzes in the podcast that Democrats' most unified priority is repealing the roughly $1 trillion in Medicare/Medicaid cuts in the One Big Beautiful Bill Act, but the next two years are more likely to be about political pressure than policy implementation. The two parties have realistic room for cooperation on site neutrality payment reform, fixing the No Surprises Act arbitration backlog, and international drug price referencing and expanding Medicare drug negotiations. Short-term substantive change is most likely at the state level — Democratic victories in Texas and Georgia could restart Medicaid expansion negotiations, and public option experiments and private equity healthcare regulation will advance in multiple states. Democrats face a key choice: build internal consensus around healthcare reform to pave the way for governing in 2028, or let healthcare once again become a dividing point in primaries.
Related articles

Why Microsoft CEO Nadella Still Backs Nvidia After Jensen Huang's Departure
Microsoft CEO Nadella publicly expresses confidence in Nvidia interim CEO Colette Kress. This article analyzes Nvidia's power transition after Jensen Huang's departure, Microsoft's compute dependency, and the trust logic of the AI supply chain.

Nadella: Critical Infrastructure Is 'Unpatchable' as AI Cybersecurity Arms Race Escalates
Microsoft CEO Nadella addresses AI cyberattack fears, saying much critical infrastructure is unpatchable, downplaying the Outlook outage, and analyzing AI's dual role in cybersecurity.

Musk Backs Jensen Huang: Firing Him Is Like Cutting Jordan
Musk says Jensen Huang is loyal to the U.S. and likens firing him to cutting Michael Jordan—highlighting politicization anxieties in the AI chip industry and defending talent value.